Skip to main content
. 2020 Sep 22;2020(9):omaa077. doi: 10.1093/omcr/omaa077

Figure 1.

Figure 1

(A) PET/CT at time of recurrence confirming FDG right upper lobe avid lesion. (B) PET/CT post two cycles of nivolumab showing no evidence of FDG avid disease. (C) Baseline audiometry showing complete loss of hearing affecting the right ear. (D) Evidence of initial recovery of low-frequency hearing after 10 days on steroids. (E) Continued improvement in hearing 3 months after discontinuation of nivolumab.